Bicara Therapeutics BCAX
NASDAQ BCAX
$18.36 +0.01 (+0.04%)
As of: Oct 21, 2026 · 12:44 PM EDT

Bicara Therapeutics (BCAX) Other Non-Current Liabilities (2023)

Updated

Bicara Therapeutics (BCAX) posted Other Non-Current Liabilities of $17,000 for Q4 2023.

Analysis

Bicara Therapeutics (BCAX) Other Non-Current Liabilities (2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,131.52 Bn 1,100.11 Bn 19.71 Bn
2 Johnson & Johnson 616.33 Bn 534.86 Bn 17.26 Bn
3 AbbVie 500.08 Bn 473.19 Bn 12.70 Bn
4 Merck 366.80 Bn 321.17 Bn 12.21 Bn
5 Novartis Ag 297.92 Bn 261.91 Bn 11.24 Bn
6 Astrazeneca 261.59 Bn 235.28 Bn 12.86 Bn
7 Amgen 234.86 Bn 190.26 Bn 7.24 Bn
8 Gilead Sciences 189.95 Bn 164.15 Bn 6.22 Bn
9 Pfizer 169.63 Bn 116.28 Bn 10.94 Bn
10 Bicara Therapeutics 1.25 Bn -490.79 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 17,000.00
API Access

Bicara Therapeutics Other Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-non-current-liabilities&ticker=BCAX&period=max&api_key=YOUR_API_KEY